By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Caladrius Biosciences (Formerly Known As NeoStem, Inc.)  

420 Lexington Ave, Suite 350

New York  New York  10170  U.S.A.
Phone: 212-584-4180 Fax: 425-696-4651




Company News
Caladrius Biosciences Establishes Cardiovascular Scientific Advisory Board To Support Ongoing Development Efforts Using CD34 Cells 6/29/2015 8:05:08 AM
Caladrius Biosciences Announces First Patient Dosed In Phase 3 Immunotherapy Trial For Melanoma 6/23/2015 6:10:04 AM
Caladrius Biosciences Announces Research Collaboration With The University of Southern California And California Institute of Technology 6/18/2015 7:26:20 AM
PCT, A Caladrius Biosciences Company, Expands Relationship With ImmunoCellular Therapeutics, Ltd (IMUC) To Provide Manufacturing For Their Phase III Trial 6/15/2015 7:51:36 AM
ImmunoCellular Therapeutics, Ltd (IMUC) Enters Into Manufacturing Agreement With PCT LLC, A Caladrius Biosciences Company, For US Production Of ICT-107 For Phase 3 Registration Trial 6/15/2015 6:10:03 AM
Caladrius Biosciences Issues Letter To Shareholders 6/9/2015 7:46:31 AM
Caladrius Biosciences Finalizes Corporate Name Change From Neostem 6/8/2015 10:10:36 AM
Neostem To Present At Two Conferences In Late June 6/4/2015 8:00:53 AM
NeoStem Announces Plans To Change Name To Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company 5/29/2015 8:55:37 AM
NeoStem, Inc. Prices $25,000,000 Public Offering Of Common Stock 5/28/2015 7:54:54 AM